Oral lichenoid reactions associated with anti‐<scp>PD</scp>‐1/<scp>PD</scp>‐L1 therapies: clinicopathological findingsV. Sibaud, Mario E. Lacouture, Viswanath Reddy Belum et al.|Journal of the European Academy of Dermatology and Venereology|2017Cited by 75
Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12).Karim Fizazi, Stéphane Culine, Loı̈c Mourey et al.|Journal of Clinical Oncology|2011Cited by 9
Nonmetastatic, high-risk prostate cancer patients with biochemical relapse after local treatment: A prospective, randomized phase III study comparing hormonal therapy ± docetaxel—An analysis of final safety results.Stéphane Oudard, Stéphane Culine, I. Latorzeff et al.|Journal of Clinical Oncology|2010Cited by 1
Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patientsCécile Vicier, Karim Fizazi, Laurence Faivre et al.|Annals of Oncology|2016Cited by 0